MorphoSys (Nasdaq:MOR) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MOR Stoklara Genel Bakış

Engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. Daha fazla detay

MOR temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Gelirin yılda 24.99% oranında artması öngörülüyor

Risk Analizi

Negatif hissedar öz sermayesi

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

MorphoSys AG Rakipler

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.7b

Amicus Therapeutics

NasdaqGM:FOLD

US$2.9b

PTC Therapeutics

NasdaqGS:PTCT

US$3.5b

Twist Bioscience

NasdaqGS:TWST

US$2.8b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti MorphoSys
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€18.96
52 Haftanın En Yüksek Seviyesi	€19.50
52 Haftanın En Düşük Seviyesi	€4.19
Beta	0.67
11 Aylık Değişim	1.94%
3 Aylık Değişim	5.69%
1 Yıllık Değişim	150.79%
33 Yıllık Değişim	38.65%
5 Yıllık Değişim	-36.95%
Halka arzdan bu yana değişim	-26.57%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	MOR	US Biotechs	US Pazar
7D	1.9%	4.3%	1.6%
1Y	150.8%	18.8%	32.3%

Getiri vs. Endüstri: MOR geçen yıl % 18.8 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: MOR geçen yıl % 32.3 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is MOR's price volatile compared to industry and market?
MOR volatility
MOR Average Weekly Movement	3.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: MOR son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: MOR 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 12% dan 3% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1992	464	Arkadius Pichota	www.morphosys.com

MorphoSys AG Temel Bilgiler Özeti

MorphoSys'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MOR temel i̇stati̇sti̇kler
Piyasa değeri	US$2.78b
Kazançlar(TTM)	-US$513.62m
Gelir(TTM)	US$264.68m

10.5x

P/S Oranı

-5.4x

F/K Oranı

MOR aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MOR gelir tablosu (TTM)
Gelir	€241.47m
Gelir Maliyeti	€60.14m
Brüt Kâr	€181.33m
Diğer Giderler	€649.90m
Kazançlar	-€468.57m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

Aug 07, 2024

Hisse başına kazanç (EPS)	-12.44
Brüt Marj	75.09%
Net Kâr Marjı	-194.05%
Borç/Özkaynak Oranı	-658.0%

MOR uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company listing is no longer active

MOR Stoklara Genel Bakış

Ödüller

Risk Analizi

MorphoSys AG Rakipler

NasdaqGS:ACAD

US$2.7b

NasdaqGM:FOLD

US$2.9b

NasdaqGS:PTCT

US$3.5b

NasdaqGS:TWST

US$2.8b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

Recent updates

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

MorphoSys: Hold Rating Until The Novartis Deal Closes

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis And MorphoSys Are A Perfect Match

Novartis Reportedly in Lead to Acquire MorphoSys

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Morphosys AG Provides Earnings Guidance for the Year 2023

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys AG Provides Earnings Guidance for the Year 2023

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

MorphoSys AG Announces Executive Changes

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

MorphoSys updates Q2 & FY22 guidance below prior provided levels

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

MorphoSys May Not Recover From Adventurous Constellation Buyout

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Health Canada Grants Marketing Authorization for Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MorphoSys AG (XTRA:MOR) completed the acquisition of Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST).

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte and MorphoSys presents new three-year data for blood cancer therapy

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys AG Reaffirms Group Financial Guidance for the Year 2021

MorphoSys reports Q1 results

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

Incyte Corporation and MorphoSys AG Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

MorphoSys AG Announces Management Changes

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Morphosys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab

MorphoSys AG, Annual General Meeting, May 19, 2021

Incyte and MorphoSys AG Announces Data Evaluating Tafasitamab with and Without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented At ASH 2020

MorphoSys AG (MOR) Investor Presentation - Slideshow